Trials / Unknown
UnknownNCT05014555
Sustained Humoral and Cell-Mediated Immunogenicity of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 400 (estimated)
- Sponsor
- GI Alliance · Academic / Other
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to determine the impact of systemic immunosuppression on sustained antibody COVID-19 concentrations in patients with IBD who received a COVID-19 vaccine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | COVID-19 Vaccine | Three-dose mRNA COVID-19 vaccine per standard of care |
Timeline
- Start date
- 2023-07-05
- Primary completion
- 2024-01-01
- Completion
- 2024-01-01
- First posted
- 2021-08-20
- Last updated
- 2023-06-18
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT05014555. Inclusion in this directory is not an endorsement.